Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia

Isa-VCd induction in NDMM patients with severe renal impairment show no new safety concerns

A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM

Novel CAR-T cell therapy shows promise against calreticulin mutant neoplasms

EHA 2024: Multiple myeloma roundup

Whole body-MRI and fluorine 18 fluorodeoxyglucose PET/CT shows promising diagnostic accuracy in multiple myeloma patients

ATRA-ATO regimen with idarubicin could become the new standard of care in high-risk acute promyelocytic leukaemia

Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in RRMM compared to standard of care in 2nd line

Ponatinib is better than imatinib for frontline treatment of newly diagnosed Ph+ acute lymphoblastic leukaemia

More effective treatment options required for patients with MM post lenalidomide exposure

Ibrutinib and venetoclax continue to provide benefits for patients with chronic CLL and SLL

Lower levels of inflammatory markers and tumour burden is linked to improvements in PFS with Ide-Cel in R/R multiple myeloma

Combination of zanubrutinib and venetoclax shows promise in high-risk TN CLL/SLL with del(17p) and/or TP53 mutation

Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM